SIGILON THERAPEUTICS, INC.
100 Binney Street, Suite 600
Cambridge, MA 02142
December 1, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Julia Griffith and Dietrich King, Division of Corporation Finance |
|
|
Re: | Sigilon Therapeutics, Inc. |
| Registration Statement on Form S-1 (File No. 333-250070) |
| Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on December 3, 2020, or as soon as possible thereafter. The Company hereby authorizes Marc Rubenstein or William Michener of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please call William Michener of Ropes & Gray LLP, counsel to the Company, at (617) 951-7247 as soon as the registration statement has been declared effective.
[Signature page follows]
|
| Very truly yours, | |
|
|
| |
|
| SIGILON THERAPEUTICS, INC. | |
|
|
| |
|
|
| |
|
| By: | /s/ Rogerio Vivaldi Coelho, M.D. |
|
| Name: | Rogerio Vivaldi Coelho, M.D. |
|
| Title: | President and Chief Executive Officer |
[Signature Page to Acceleration Request]